Tirzepatide (CAS 2023788-19-2, molecular formula C225H348N48O68) is a synthetic dual GIP and GLP-1 receptor agonist peptide studied for its interaction with incretin receptor signalling pathways. PhaseOne supplies Tirzepatide to researchers across Australia as a high-purity lyophilised powder, independently HPLC verified at ≥99% purity per batch.
As a dual-incretin research peptide, Tirzepatide is studied alongside related metabolic peptides such as Retatrutide within Australian peptide research, manufactured to research-grade standards and independently third-party tested for identity and consistency, with every order shipped Australia-wide. (!) Full Certificate of Analysis available for every batch view here.
What is Tirzepatide?
Tirzepatide is a synthetic 39-amino-acid peptide and dual GIP/GLP-1 receptor agonist, studied within Australian peptide research for its interaction with incretin receptor signalling pathways.
How does Tirzepatide differ from Retatrutide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist, whereas Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist; the two have distinct receptor profiles studied within metabolic peptide research. (!) Compare them in our Retatrutide vs Tirzepatide guide, or view our Retatrutide.
Storage & reconstitution
Unreconstituted Tirzepatide should be stored refrigerated and protected from light, and is commonly reconstituted with bacteriostatic water prior to research preparation. (!) Read our reconstitution guide.
How is purity verified?
Each PhaseOne batch is independently verified by third-party HPLC analysis, with a Certificate of Analysis available for every order shipped across Australia.
What research category does Tirzepatide fall under?
All products supplied by PhaseOne are intended strictly for laboratory research purposes only. Products are not intended for human consumption, therapeutic use, cosmetic use, veterinary use, or diagnostic applications.
